《对肺病和肺移植患者接受非类固醇类免疫抑制药的监测》内容预览

3.1a. For patients who will undergo anti-TNF-atherapy, a chest radiograph is recommendedprior to treatment (Grade 1C).

3.1b. For patients who will undergo anti-TNF-atherapy, a tuberculin skin test is recommendedto screen for latent TB prior to treatment(Grade 1C).

3.1c. For patients who will undergo anti-TNF-atherapy and present with a chest radiographconsistent with prior TB or a positive tuberculinskin test and/or are high-risk individuals, activeTB infection should be excluded prior to treat-ment with adalimumab (Grade 1C), etanercept(Grade 1B), or infliximab (Grade 1B).

3.1d. For patients with latent Mycobacteriumtuberculosis, active prophylactic treatment fol-lowing published guidelines before initiation ofanti-TNF-a therapy is recommended (Grade 1B).

3.1e. For patients with latent M tuberculosis whowill undergo anti-TNF-a therapy, close monitor-ing for TB is recommended for up to 6 monthsafter discontinuing therapy (Grade 1C).

3.1f. For patients who develop symptoms indic-ative of TB, prompt evaluation for active diseaseis recommended (Grade 1C).

3.1g. For patients with known grade III or IVNew York Heart Association class heart failure,administration of adalimumab (Grade 1C), etan-ercept (Grade 1C), and infliximab (Grade 1B) isnot recommended.

点击下载***：《对肺病和肺移植患者接受非类固醇类免疫抑制药的监测》